The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist

David G. Sawutz; Joseph M. Salvino; Roland E. Dolle; Fran Casiano; Susan J. Ward; Wayne T. Houck; David M. Faunce; Brent D. Douty; Eugene Baizman; Mohammed M.A. Awad; François Marceau; Peter R. Seoane

doi:10.1073/pnas.91.11.4693

The nonpeptide WIN 64338 is a bradykinin B₂ receptor antagonist

David G. Sawutz, Joseph M. Salvino, Roland E. Dolle, Fran Casiano, Susan J. Ward, Wayne T. Houck, David M. Faunce, Brent D. Douty, Eugene Baizman, Mohammed M.A. Awad, François Marceau, Peter R. Seoane

Research output: Contribution to journal › Article › peer-review

92 Scopus citations

Abstract

We report the synthesis and in vitro biological activity of the nonpeptide bradykinin receptor antagonist WIN 64338, [[4-[[2- [[bis(cyclohexylamino)methylene]amino]-3-(2-naphthyl)-1- oxopropyl]amino]phenyl]methyl]tributylphosphonium chloride monohydrochloride. WIN 64338 inhibits [³H]bradykinin binding to the bradykinin B₂ receptor on human IMR-90 cells with a binding inhibition constant (K(i)) of 64 ± 8 nM and demonstrates competitive inhibition of bradykinin-stimulated ⁴⁵Ca²⁺ efflux from IMR-90 cells (pA₂ = 7.1). The antagonist inhibits bradykinin- mediated guinea pig ileum contractility (pA₂ = 8.2) and has significantly weaker activity against acetylcholine-induced contractility in the same preparation. WIN 64338 is not active in a rabbit aorta bradykinin B₁ receptor assay, demonstrating that it is a selective bradykinin B₂ receptor antagonist. The compound inhibits [³H]quinuclidinyl benzilate binding to the rat brain muscarinic receptor (K(i) = 350 nM) but is 25- to 100-fold more selective for the bradykinin receptor compared with other receptors against which it has been tested. Synthesis of WIN 64338 has provided a nonpeptide competitive bradykinin B₂ antagonist active in both bradykinin radioligand binding and functional assays.

Original language	English
Pages (from-to)	4693-4697
Number of pages	5
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	91
Issue number	11
DOIs	https://doi.org/10.1073/pnas.91.11.4693
State	Published - May 24 1994

Access to Document

10.1073/pnas.91.11.4693

Cite this

Sawutz, D. G., Salvino, J. M., Dolle, R. E., Casiano, F., Ward, S. J., Houck, W. T., Faunce, D. M., Douty, B. D., Baizman, E., Awad, M. M. A., Marceau, F., & Seoane, P. R. (1994). The nonpeptide WIN 64338 is a bradykinin B₂ receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America, 91(11), 4693-4697. https://doi.org/10.1073/pnas.91.11.4693

@article{098dc32fbfdc497d9aa676aacab6fd5d,

title = "The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist",

abstract = "We report the synthesis and in vitro biological activity of the nonpeptide bradykinin receptor antagonist WIN 64338, [[4-[[2- [[bis(cyclohexylamino)methylene]amino]-3-(2-naphthyl)-1- oxopropyl]amino]phenyl]methyl]tributylphosphonium chloride monohydrochloride. WIN 64338 inhibits [3H]bradykinin binding to the bradykinin B2 receptor on human IMR-90 cells with a binding inhibition constant (K(i)) of 64 ± 8 nM and demonstrates competitive inhibition of bradykinin-stimulated 45Ca2+ efflux from IMR-90 cells (pA2 = 7.1). The antagonist inhibits bradykinin- mediated guinea pig ileum contractility (pA2 = 8.2) and has significantly weaker activity against acetylcholine-induced contractility in the same preparation. WIN 64338 is not active in a rabbit aorta bradykinin B1 receptor assay, demonstrating that it is a selective bradykinin B2 receptor antagonist. The compound inhibits [3H]quinuclidinyl benzilate binding to the rat brain muscarinic receptor (K(i) = 350 nM) but is 25- to 100-fold more selective for the bradykinin receptor compared with other receptors against which it has been tested. Synthesis of WIN 64338 has provided a nonpeptide competitive bradykinin B2 antagonist active in both bradykinin radioligand binding and functional assays.",

author = "Sawutz, {David G.} and Salvino, {Joseph M.} and Dolle, {Roland E.} and Fran Casiano and Ward, {Susan J.} and Houck, {Wayne T.} and Faunce, {David M.} and Douty, {Brent D.} and Eugene Baizman and Awad, {Mohammed M.A.} and Fran{\c c}ois Marceau and Seoane, {Peter R.}",

year = "1994",

month = may,

day = "24",

doi = "10.1073/pnas.91.11.4693",

language = "English",

volume = "91",

pages = "4693--4697",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

number = "11",

}

TY - JOUR

T1 - The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist

AU - Sawutz, David G.

AU - Salvino, Joseph M.

AU - Dolle, Roland E.

AU - Casiano, Fran

AU - Ward, Susan J.

AU - Houck, Wayne T.

AU - Faunce, David M.

AU - Douty, Brent D.

AU - Baizman, Eugene

AU - Awad, Mohammed M.A.

AU - Marceau, François

AU - Seoane, Peter R.

PY - 1994/5/24

Y1 - 1994/5/24

N2 - We report the synthesis and in vitro biological activity of the nonpeptide bradykinin receptor antagonist WIN 64338, [[4-[[2- [[bis(cyclohexylamino)methylene]amino]-3-(2-naphthyl)-1- oxopropyl]amino]phenyl]methyl]tributylphosphonium chloride monohydrochloride. WIN 64338 inhibits [3H]bradykinin binding to the bradykinin B2 receptor on human IMR-90 cells with a binding inhibition constant (K(i)) of 64 ± 8 nM and demonstrates competitive inhibition of bradykinin-stimulated 45Ca2+ efflux from IMR-90 cells (pA2 = 7.1). The antagonist inhibits bradykinin- mediated guinea pig ileum contractility (pA2 = 8.2) and has significantly weaker activity against acetylcholine-induced contractility in the same preparation. WIN 64338 is not active in a rabbit aorta bradykinin B1 receptor assay, demonstrating that it is a selective bradykinin B2 receptor antagonist. The compound inhibits [3H]quinuclidinyl benzilate binding to the rat brain muscarinic receptor (K(i) = 350 nM) but is 25- to 100-fold more selective for the bradykinin receptor compared with other receptors against which it has been tested. Synthesis of WIN 64338 has provided a nonpeptide competitive bradykinin B2 antagonist active in both bradykinin radioligand binding and functional assays.

AB - We report the synthesis and in vitro biological activity of the nonpeptide bradykinin receptor antagonist WIN 64338, [[4-[[2- [[bis(cyclohexylamino)methylene]amino]-3-(2-naphthyl)-1- oxopropyl]amino]phenyl]methyl]tributylphosphonium chloride monohydrochloride. WIN 64338 inhibits [3H]bradykinin binding to the bradykinin B2 receptor on human IMR-90 cells with a binding inhibition constant (K(i)) of 64 ± 8 nM and demonstrates competitive inhibition of bradykinin-stimulated 45Ca2+ efflux from IMR-90 cells (pA2 = 7.1). The antagonist inhibits bradykinin- mediated guinea pig ileum contractility (pA2 = 8.2) and has significantly weaker activity against acetylcholine-induced contractility in the same preparation. WIN 64338 is not active in a rabbit aorta bradykinin B1 receptor assay, demonstrating that it is a selective bradykinin B2 receptor antagonist. The compound inhibits [3H]quinuclidinyl benzilate binding to the rat brain muscarinic receptor (K(i) = 350 nM) but is 25- to 100-fold more selective for the bradykinin receptor compared with other receptors against which it has been tested. Synthesis of WIN 64338 has provided a nonpeptide competitive bradykinin B2 antagonist active in both bradykinin radioligand binding and functional assays.

UR - http://www.scopus.com/inward/record.url?scp=0028229872&partnerID=8YFLogxK

U2 - 10.1073/pnas.91.11.4693

DO - 10.1073/pnas.91.11.4693

M3 - Article

C2 - 8197121

AN - SCOPUS:0028229872

SN - 0027-8424

VL - 91

SP - 4693

EP - 4697

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 11

ER -

The nonpeptide WIN 64338 is a bradykinin B₂ receptor antagonist

Abstract

Access to Document

Other files and links

Fingerprint

Cite this